Investor Presentaiton

Double digit growth Growth path of CarrageloseⓇ maintained in 2020 Y-o-Y comparison of Revenues (in m€) +35% +40% +38% 2.3 1.7 1.3 1.0 0.8 0.9 Q1 Q1 Q2 Q2 2019 2020 2019 2020 H1 2019 2020 H1 Margin H1 2020 H1 2019 Sale of goods 2.0 1.5 Cost of goods sold (1.5) (1.0) Gross result Gross margin 0.5 0.4 26.4% 28.7% Excludes extra ordinary effect from a licensing contract marino med Comments Double digit growth in revenue was achieved from the sale of products in the CarrageloseⓇ segment ■ First revenues from services provided through application of the MarinosolvⓇ platform were generated ■ Return of certain regions results in extra ordinary revenue and gives opportunity to address underserved markets COVID-19 pandemic leads to strong order book - challenging the supply chain ■ Various measures in progress to increase capacities with suppliers and improve speed of the supply chain 13

View entire presentation